HeyJaredTara Haelle
- Indexed articles, last 90 days
- 12
- Latest publication
- Sep 16, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 13, 2026
Latest articles
Two More HIV Cure Cases Reported at AIDS 2026 (opens the original)
Read excerpt
Two additional cases of curing HIV through otherwise indicated stem cell transplant were reported at AIDS 2026 this year, bringing the total number of cured HIV cases reported to date to 13. One of these cases, the “Essen patient” occurred despite complex virologic conditions and being the first with mixed HIV-1 tropism, reported Carina Elsner, of the Institute for Virology at University Medicine Essen in Essen, Germany. “This is providing new insights into the role of viral tropism in HIV cure,
Once-Monthly PrEP Drug Could Be Manufactured for $3 a Year (opens the original)
Read excerpt
The investigational once-monthly oral preexposure prophylaxis (PrEP) drug alimatravir could be manufactured for as little as $3 per person per year, according to an analysis presented July 28 at the annual meeting of AIDS 2025 in Rio de Janeiro. Yet Merck’s preliminary access plan does not extend its voluntary licenses to all low- and middle-income countries with substantial or rising HIV incidence — including several countries participating in phase 3 trials — and the company has not committed
ACOG Strengthens Ovarian Cancer Prevention Guidance (opens the original)
Read excerpt
The American College of Obstetricians and Gynecologists (ACOG) has updated and strengthened its recommendation for salpingectomies for prevention of ovarian cancer on the basis of more evidence that these procedures provide substantial risk reduction. The new guidance applies to women at average risk for ovarian cancer, separate from the guidance for those with a higher risk due to genetics, such as having a BRCA mutation or a family history. “It’s critical that ob/gyns update themselves on the
HIV Resistance Assay Offers Quick, Low-Cost Results for RTs (opens the original)
Read excerpt
An investigational test for HIV drug resistance has the potential to provide results on phenotypic susceptibility within a few hours at a low cost, according to research presented at the annual meeting of AIDS 2026 in Rio de Janeiro, Brazil. “We set out to answer if an enzyme activity assay could achieve necessary sensitivity for simultaneous HIV viral load and drug resistance testing,” Dorothy Mims, MS, bioengineering PhD student and STD AIDS Research Fellow at the University of Washington in S
Dolutegravir ART Receives FDA Approval for Newborns With HIV (opens the original)
Read excerpt
The antiretroviral dolutegravir (Tivicay PD, ViiV Healthcare) is now the first second-generation integrase strand transfer inhibitor (INSTI) available for use with other antiretroviral agents in newborns with HIV, following the FDA's August 26 approval of the drug for infants under 4 weeks old weighing at least 2 kg. "This is a welcome expansion of our treatment options for newborns with HIV," Carlos Oliveira, MD, PhD, a pediatric infectious diseases specialist at Yale Medicine and medical direc
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.